Intra-lesional injection of the novel PKC activator EBC-46 rapidly ablates tumors in mouse models

PLoS ONE

Volumn 9, Issue 10, 2014, Pages

  Boyle, Glen M ^a   D'Souza, Marjorie M A ^a,b   Pierce, Carly J ^a   Adams, Ryan A ^a,b,c   Cantor, Aaron S ^a   Johns, Jenny P ^a   Maslovskaya, Lidia ^a   Gordon, Victoria A ^d   Reddell, Paul W ^d   Parsons, Peter G ^a  

^a QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

^b UNIVERSITY OF QUEENSLAND   (Australia)

^c PRINCESS ALEXANDRA HOSPITAL   (Australia)

^d QBiotics Ltd   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CD31 ANTIGEN; EBC 46; PHORBOL 13 ACETATE 12 MYRISTATE; PROTEIN KINASE C ALPHA; PROTEIN KINASE C BETA1; PROTEIN KINASE C BETA2; PROTEIN KINASE C GAMMA; PROTEIN SERINE THREONINE KINASE; UNCLASSIFIED DRUG; BISINDOLYLMALEIMIDE I; DITERPENE; EBC-46; INDOLE DERIVATIVE; MALEIMIDE DERIVATIVE; PROTEIN KINASE C; PROTEIN KINASE INHIBITOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CHEMOTHERAPY; CANCER INHIBITION; CANCER REGRESSION; CELL DEATH; CELL MEMBRANE PERMEABILITY; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENCY; DRUG RESPONSE; DRUG STRUCTURE; ENZYME ACTIVATION; EX VIVO STUDY; HEAD AND NECK CANCER; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; INTRALESIONAL DRUG ADMINISTRATION; ISOGRAFT; MALE; MOUSE; MOUSE MODEL; NEUTROPHIL; NONHUMAN; OXIDATION; POLYMORPHONUCLEAR CELL; TUMOR ABLATION; TUMOR NECROSIS; TUMOR XENOGRAFT; ANIMAL; ANTAGONISTS AND INHIBITORS; METABOLISM; NEOPLASMS; PATHOLOGY; TUMOR CELL LINE; XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; DITERPENES; HETEROGRAFTS; HUMANS; INDOLES; INJECTIONS, INTRALESIONAL; MALEIMIDES; MICE; NEOPLASMS; PROTEIN KINASE C; PROTEIN KINASE INHIBITORS;

EID: 84907528854     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0108887     Document Type: Article

References (34)

1. van Herpen C.M., van der Voort R, van der Laak JA, Klasen IS, de Graaf AO, et al. (2008) Intratumoral rhIL-12 administration in head and neck squamous cell carcinoma patients induces B cell activation. Int J Cancer 123: 2354-2361.
2. Castro DJ, Sridhar KS, Garewal H.S., Mills GM, Wenig BL, et al. (2003) Intratumoral cisplatin/epinephrine gel in advanced head and neck cancer: a multicenter, randomized, double-blind, phase III study in North America. Head Neck 25: 717-731.
3. Good LM, Miller MD, High W.A. (2011) Intralesional agents in the management of cutaneous malignancy: a review. J Am Acad Dermatol 64: 413-422.
4. Weinberg BD, Blanco E, Gao J. (2008) Polymer implants for intratumoral drug delivery and cancer therapy. J Pharm Sci 97: 1681-1702.
5. Newton AC (2010) Protein kinase C: poised to signal. Am J Physiol Endocrinol Metab 298: E395-402.
6. Breitkreutz D, Braiman-Wiksman L, Daum N., Denning MF, Tennenbaum T. (2007) Protein kinase C family: on the crossroads of cell signaling in skin and tumor epithelium. J Cancer Res Clin Oncol 133: 793-808.
7. Podar K, Raab MS, Chauhan D, Anderson K.C. (2007) The therapeutic role of targeting protein kinase C in solid and hematologic malignancies. Expert Opin Investig Drugs 16: 1693-1707.
8. Ali AS, Ali S, El-Rayes BF, Philip P.A., Sarkar F.H. (2009) Exploitation of protein kinase C: a useful target for cancer therapy. Cancer Treat Rev 35: 1-8.
9. Mochly-Rosen D., Das K, Grimes K.V. (2012) Protein kinase C, an elusive therapeutic target? Nat Rev Drug Discov 11: 937-957.
10. Robertson MJ, Kahl BS, Vose J.M., de Vos S, Laughlin M, et al (2007) Phase II study of enzastaurin, a protein kinase C beta inhibitor, in patients with relapsed or refractory diffuse large B-cell lymphoma. J Clin Oncol 25: 1741-1746.
11. Oh Y, Herbst RS, Burris H, Cleverly A., Musib L, et al. (2008) Enzastaurin, an oral serine/threonine kinase inhibitor, as second- or third-line therapy of non-small-cell lung cancer. J Clin Oncol 26: 1135-1141.
12. Han ZT, Tong YK, He L.M., Zhang Y., Sun JZ, et al. (1998) 12-O-Tetradecanoylphorbol-13-acetate (TPA)-induced increase in depressed white blood cell counts in patients treated with cytotoxic cancer chemotherapeutic drugs. Proc Natl Acad Sci U S A 95: 5362-5365.
13. Han ZT, Zhu XX, Yang R.Y., Sun JZ, Tian GF, et al. (1998) Effect of intravenous infusions of 12-O-tetradecanoylphorbol-13-acetate (TPA) in patients with myelocytic leukemia: preliminary studies on therapeutic efficacy and toxicity. Proc Natl Acad Sci U S A 95: 5357-5361.
14. Ogbourne SM, Suhrbier A, Jones B., Cozzi SJ, Boyle GM, et al. (2004) Antitumor activity of 3-ingenyl angelate: plasma membrane and mitochondrial disruption and necrotic cell death. Cancer Res 64: 2833-2839.
15. Challacombe JM, Suhrbier A, Parsons P.G., Jones B., Hampson P, et al. (2006) Neutrophils are a key component of the antitumor efficacy of topical chemotherapy with ingenol-3-angelate. J Immunol 177: 8123-8132.
16. Martin G, Swanson N. (2013) Clinical findings using ingenol mebutate gel to treat actinic keratoses. J Am Acad Dermatol 68: S39-48.
17. Gras J (2013) Ingenol mebutate: a new option for actinic keratosis treatment. Drugs Today (Barc) 49: 15-22.
18. Cozzi SJ, Ogbourne SM, James C, Rebel H.G., de Gruijl FR, et al. (2012) Ingenol mebutate field-directed treatment of UVB-damaged skin reduces lesion formation and removes mutant p53 patches. J Invest Dermatol 132: 1263-1271.
19. Cozzi SJ, Le TT, Ogbourne S.M., James C., Suhrbier A. (2013) Effective treatment of squamous cell carcinomas with ingenol mebutate gel in immunologically intact SKH1 mice. Arch Dermatol Res 305: 79-83.
20. Corbett TH, Griswold DP Jr, Roberts BJ, Peckham JC, Schabel FM Jr (1975) Tumor induction relationships in development of transplantable cancers of the colon in mice for chemotherapy assays, with a note on carcinogen structure. Cancer Res 35: 2434-2439.
21. Lafreniere R, Rosenberg S.A. (1986) A novel approach to the generation and identification of experimental hepatic metastases in a murine model. J Natl Cancer Inst 76: 309-322.
22. Pavey S, Johansson P, Packer L., Taylor J, Stark M, et al (2004) Microarray expression profiling in melanoma reveals a BRAF mutation signature. Oncogene 23: 4060-4067.
23. Chen TR (1977) In situ detection of mycoplasma contamination in cell cultures by fluorescent Hoechst 33258 stain. Exp Cell Res 104: 255-262.
24. Skehan P, Storeng R, Scudiero D., Monks A, McMahon J, et al (1990) New colorimetric cytotoxicity assay for anticancer-drug screening. J Natl Cancer Inst 82: 1107-1112.
25. Mason SA, Cozzi SJ, Pierce C.J., Pavey SJ, Parsons PG, et al. (2010) The induction of senescence-like growth arrest by protein kinase C-activating diterpene esters in solid tumor cells. Invest New Drugs 28: 575-586.
26. Keisari Y, Flescher E, Geva I. (1984) Macrophage oxidative burst and related cytotoxicity. I. Differential activation by tumor-promoting and non-tumor-promoting phorbol esters. Int J Cancer 34: 845-848.
27. Ochi T, Ishiguro T, Ohsawa M. (1985) Release of hydrogen peroxide from polymorphonuclear leukocytes stimulated with lambda-carrageenan. Jpn J Exp Med 55: 245-249.
28. Rimessi A, Rizzuto R, Pinton P. (2007) Differential recruitment of PKC isoforms in HeLa cells during redox stress. Cell Stress Chaperones 12: 291-298.
29. Li L, Shukla S, Lee A., Garfield SH, Maloney DJ, et al. (2010) The skin cancer chemotherapeutic agent ingenol-3-angelate (PEP005) is a substrate for the epidermal multidrug transporter (ABCB1) and targets tumor vasculature. Cancer Res 70: 4509-4519.
30. Lum H, Malik A.B. (1994) Regulation of vascular endothelial barrier function. Am J Physiol 267: L223-241.
31. Nagpala PG, Malik AB, Vuong P.T., Lum H. (1996) Protein kinase C beta 1 overexpression augments phorbol ester-induced increase in endothelial permeability. J Cell Physiol 166: 249-255.
32. Jain RK (2005) Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 307: 58-62.
33. Daley JM, Thomay AA, Connolly M.D., Reichner JS, Albina J.E. (2008) Use of Ly6G-specific monoclonal antibody to deplete neutrophils in mice. J Leukoc Biol 83: 64-70.
34. Song X, Lopez-Campistrous A, Sun L., Dower NA, Kedei N, et al. (2013) RasGRPs are targets of the anti-cancer agent ingenol-3-angelate. PLoS One 8: e72331.